SCHEMBL3166158

SCHEMBL3166158

O=C(NCc1ccc(OC(F)(F)F)cc1)c1ccc(S(=O)(=O)Nc2nccs2)c(F)c1

nearest known ligand 0.78

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 10/20 0.78
SCN9A Q15858 9/20 0.78
SCN1A P35498 2/20 0.78
SCN5A Q14524 2/20 0.78
SCN2A Q99250 2/20 0.78
SCN8A Q9UQD0 2/20 0.78
SCN10A Q9Y5Y9 2/20 0.78
KCNH2 Q12809 1/20 0.78
EPHX2 P34913 1/20 0.49
NR1H4 Q96RI1 1/20 0.49
HTR2C P28335 1/20 0.46
ALDH1A1 P00352 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
HPGD P15428 1/20 0.45
CYP2C19 P33261 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3166978 0.91 SCN3A (0.74) SCN3ASCN9ASCN1ASCN5ASCN2A
SCHEMBL3161293 0.90 SCN3A (0.75) SCN3ASCN9ASCN1ASCN5ASCN2A
SCHEMBL3167092 0.90 SCN3A (0.83) SCN3ASCN9ASCN1ASCN5ASCN2A
SCHEMBL3161008 0.90 SCN3A (0.86) SCN3ASCN9ASCN1ASCN5ASCN2A
SCHEMBL3166193 0.88 SCN3A (0.76) SCN3ASCN9ASCN1ASCN5ASCN2A
SCHEMBL3119441 0.88 SCN3A (1.00) SCN3ASCN9ASCN1ASCN5ASCN2A
SCHEMBL3171623 0.86 SCN3A (1.00) SCN3ASCN9ASCN1ASCN5ASCN2A
SCHEMBL3167695 0.85 SCN3A (0.71) SCN3ASCN9ASCN1ASCN5ASCN2A
SCHEMBL3168693 0.85 SCN3A (0.71) SCN3ASCN9ASCN1ASCN5ASCN2A
SCHEMBL3169276 0.84 SCN3A (0.61) SCN3ASCN9ASCN1ASCN5ASCN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SCN3A 13/4885SCN9A 51/4885SCN1A 6/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN3A 13/4885SCN9A 51/4885SCN1A 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.